Patents Assigned to ANTECIP BIOVENTURES II LLC
  • Patent number: 9623038
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: April 18, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventors: Herriot Tabuteau, Graeme Jones
  • Patent number: 9623036
    Abstract: Methods for the safe administration of imidazole or imidazolium compounds, and conditions that may be treated by these methods, are described herein.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: April 18, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventors: Herriot Tabuteau, Jaro I. Karppinen
  • Patent number: 9623037
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: April 18, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9616077
    Abstract: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The oral bioavailability of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: April 11, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9616078
    Abstract: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The oral bioavailability of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: April 11, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9610300
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: April 4, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventors: Herriot Tabuteau, Graeme Jones
  • Patent number: 9585901
    Abstract: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome (CRPS). The oral bioavailability of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: March 7, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9585902
    Abstract: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The oral bioavailability of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: March 7, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9579323
    Abstract: Disclosed herein are methods of treating pain using RANK/RANKL antagonists.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: February 28, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9539268
    Abstract: Therapeutic compositions comprising substituted imidazole or imidazolium compounds may be used for a number of medical purposes, such as treatment of undesirable conditions or diseases, including disease or conditions related to bone, cancer, and/or pain.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: January 10, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9522157
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: December 20, 2016
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9517242
    Abstract: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The bioavailability of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: December 13, 2016
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9511081
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: December 6, 2016
    Assignee: Antecip Bioventures II, LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9493571
    Abstract: Disclosed herein are methods of treating pain using comprising RANK/RANKL antagonists.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: November 15, 2016
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9486450
    Abstract: This disclosure relates to methods administering hydroxybupropion or a prodrug thereof in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and hydroxybupropion or a prodrug of hydroxybupropion are also disclosed.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: November 8, 2016
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9474731
    Abstract: This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: October 25, 2016
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9457023
    Abstract: This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: October 4, 2016
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9457025
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: October 4, 2016
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9427403
    Abstract: Methods for the safe administration of imidazole or imidazolium compounds, and conditions that may be treated by these methods, are described herein.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: August 30, 2016
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9421176
    Abstract: This disclosure relates to methods of increasing dextromethorphan plasma levels comprising co-administering hydroxybupropion, or a prodrug thereof, and dextromethorphan to a human being in need of treatment with dextromethorphan. Dosage forms, drug delivery systems, and methods related to dextromethorphan and hydroxybupropion or a prodrug of bupropion are also disclosed.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: August 23, 2016
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau